openPR Logo
Press release

Global Lifitegrast Ophthalmic Solution Market is Driven by Rising Prevalence of Dry Eye Syndrome Worldwide

02-22-2017 02:21 PM CET | Health & Medicine

Press release from: TMR

Global Lifitegrast Ophthalmic Solution Market is Driven

Lifitegrast, available under the trade name Xiidra is the first U.S. FDA approved drug for treating the signs and symptoms of dry eye syndrome. Dry eye syndrome, also referred to as dry eye disease is a chronic disorder, which is related to lack of tears in order to maintain sufficient moisture in the eye. The condition is either due to less production of tears or quick drying of tears in the eye. Across the world, over 300 million people are reckoned to be suffering from this condition.

Request a PDF Brochure with Report Analysis: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13844

Dry eye disease (DED) involves pain, redness, light sensitivity, blurred vision, burning, and inflammation. The primary factors for DED include dry environment, allergy, sun exposure, smoke exposure, heat or chemical burns, aging, previous surgery, contact lenses or infection. At present, there are several treatment approaches available for managing dry eye syndrome, which includes lubricant treatments, anti-inflammatory treatments, autologous serum eye drops, and surgery.

The report presents a comprehensive evaluation of the Xiidra market. This includes analyzing the historic and current performance of the market for future estimates of the growth trajectory of the market.

The assessment of the vendor landscape makes for an interesting read as analysts have not only mentioned the top players in the market but have also profiled them in detail. Vital aspects such as business overview, business strategies, product portfolio, financial standing, and recent developments have been taken into consideration to assess the performance of the top players during the forecast period. Using SWOT analysis, readers are provided a clear understanding of the indicators of strengths, weakness, opportunities, and threats of each of the company.

The rising prevalence of dry eye syndrome (DES) across the world is the primary factor attributable to the growth of the Lifitegrast ophthalmic solution market. Diabetes, rheumatoid arthritis, thyroid disorders, lupus, and vitamin A deficiency are some of the underpinning factors that are accounted for the increasing prevalence of dry eye syndrome.

Being the first to receive FDA approval for treating the sign as well as symptoms of DES, the Xiidra market is expected to rise exponentially in the near future. The increasing demand for advanced treatment options for DES is expected to be favorable for the growth of the Lifitegrast ophthalmic solution market. The rising geriatric population across the world that is prone to several health conditions also accounts for the high prevalence of dry eye syndrome as a secondary condition.

Dry eye syndrome was earlier not considered seriously as it did not affect everyday functioning. However, the rising awareness about the ill-effects of dry eye syndrome is expected to favor the market’s growth exponentially. Moreover, increasing awareness about the management of this condition is further assisting the market’s growth.

In present times, high level of pollution and rising industrialization is often an underlying factor for the rising prevalence of dry eye disease. However, with rising awareness about the diagnosis and treatment of the disorder will augment the growth of Xiidra market.

Despite the increasing prevalence of dry eye disease, the underdiagnosis of the condition is restraining the market’s growth. Moreover, the trend among patients to render self-medication remains a major restraint for the growth of the Xiidra market.

Browse Research Report: http://www.transparencymarketresearch.com/lifitegrast-ophthalmic-solution-market.html

Some of the key players in the global market for dry eye syndrome include Novartis AG, Allergan Inc., Cellzome GmbH, NicOx SA, Bridge Pharma Inc., and Santen Pharmaceutical Co. Ltd.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Lifitegrast Ophthalmic Solution Market is Driven by Rising Prevalence of Dry Eye Syndrome Worldwide here

News-ID: 445523 • Views: 247

More Releases from TMR

01-17-2020 | Health & Medicine
TMR
Emerging Trends: Prenatal Vitamin Supplements Market Set For Rapid Growth & Tren …
The demand within the global market for prenatal vitamin supplements has been rising on account of the focus given on the health of pregnant women, finds Transparency Market Research (TMR). The presence of a stellar industry for women healthcare has also aided the growth of the global prenatal vitamin supplements market. It is expected that the market vendors in the global prenatal vitamin supplements market would capitalise on innovative marketing
01-17-2020 | Health & Medicine
TMR
Corporate Wellness Market : Huge Growth Opportunities and Forecast to 2026
The demand within the global market for corporate wellness has been rising on account of the need to maintain integrity within the business sector, finds Transparency Market Research (TMR). The growing number of corporate entities in the global business domain has played to the advantage of the vendors operating in the global corporate wellness market. The market vendors are capitalising on the mammoth-sized business entities in order to gain business
01-17-2020 | Health & Medicine
TMR
Healthcare Industry Dynamics: Peptide Therapeutics Market Expand Their Businesse …
The overall growth of the global peptide therapeutics market rides on the back of rising expenditure on research and development activities by several pharmaceutical organizations. Furthermore, many peptide-based drug companies are making entry into the market. Until 2018, nearly 100 peptide therapeutics were utilized commercially for many clinical indications. In addition to that, around 100 varieties of therapeutics are in the advanced phase of clinical development. Another 200 other types
01-17-2020 | Health & Medicine
TMR
Know How Pharmaceutical Robots Market is Trending in Key Regions to Reach at Nex …
The global pharmaceutical robots market is predicted in a report by Transparency Market Research (TMR) to witness high adoption of regional expansion, new product development, and merger and acquisition as key business strategies. This could be evidenced by the addition of three new regional training centers, relocation of three facilities, and opening of four new facilities of FANUC America Corporation in 2016. In the following year, Universal Robots opened its

All 5 Releases


More Releases for Lifitegrast

Lifitegrast Ophthalmic Solution Market Size, Status and Forecast to 2024
Lifitegrast, available under the trade name Xiidra is the first U.S. FDA approved drug for treating the signs and symptoms of dry eye syndrome. Dry eye syndrome, also referred to as dry eye disease is a chronic disorder, which is related to lack of tears in order to maintain sufficient moisture in the eye. The condition is either due to less production of tears or quick drying of tears in
Lifitegrast Ophthalmic Solution Market Segments and Key Trends 2016 - 2024
Lifitegrast Ophthalmic Solution Market: Overview Lifitegrast, available under the trade name Xiidra is the first U.S. FDA approved drug for treating the signs and symptoms of dry eye syndrome. Dry eye syndrome, also referred to as dry eye disease is a chronic disorder, which is related to lack of tears in order to maintain sufficient moisture in the eye. The condition is either due to less production of tears or quick
Lifitegrast Ophthalmic Solution Market to Reflect Impressive Growth Rate During …
Lifitegrast, available under the trade name Xiidra is the first U.S. FDA approved drug for treating the signs and symptoms of dry eye syndrome. Dry eye syndrome, also referred to as dry eye disease is a chronic disorder, which is related to lack of tears in order to maintain sufficient moisture in the eye. The condition is either due to less production of tears or quick drying of tears in
Lifitegrast Ophthalmic Solution Market | Analysis and Forecast up to 2024
Lifitegrast Ophthalmic Solution Market: Overview Lifitegrast, available under the trade name Xiidra is the first U.S. FDA approved drug for treating the signs and symptoms of dry eye syndrome. Dry eye syndrome, also referred to as dry eye disease is a chronic disorder, which is related to lack of tears in order to maintain sufficient moisture in the eye. The condition is either due to less production of tears or quick
02-03-2017 | Health & Medicine
TMR
Lifitegrast Ophthalmic Solution Market: Increasing Demand for Advance Treatment …
Lifitegrast is an integrin antagonist that reduces T-cell-mediated inflammation associated with dry eye disease (DED). This molecule was in pipeline for past few years and several clinical trials have been performed to test its efficacy in treating the signs and symptoms of dry eye syndrome. Avail a Sample of Research Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13844 In July 2016, lifitegrast ophthalmic solution (5%) under the brand name Xiidra by Shire plc was granted an approval from
01-13-2017 | Health & Medicine
TMR
Lifitegrast Ophthalmic Solution Market: Growing Awareness Regarding Dry Eye Synd …
Dry eye syndrome (DES) also called as dry eye disease (DED) or keratoconjunctivitis sicca (KCS), is a chronic disease that leads to lack of tears to maintain sufficient moisture to the eye. This condition is either a sign of less production of tears or quick drying of the film of tears. More than 300 million people are estimated to suffer from this condition. This medical condition is associated with symptoms